Even though more research is required to elucidate the implementation of those ascertainments in relation to cSCC, targeting Dsg2 or IL-8 could enhance the susceptibility of SCC cells to immune agents and ameliorate provided therapy. This evidence concerns the gene CXCL8 and skin squamous cell carcinoma.